HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

suppressor glycolipid S23

synthetic glycolipid analog of alpha-galactosylceramide with an elongated sphingosine chain; structure in first source

Also Known As:

SGL-S23

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kaieda, Shinjiro: 1 article (06/2007)
2.	Miyake, Sachiko: 1 article (06/2007)
3.	Oki, Shinji: 1 article (06/2007)
4.	Tomi, Chiharu: 1 article (06/2007)
5.	Yamamura, Takashi: 1 article (06/2007)

Related Diseases

1.

Arthritis (Polyarthritis)

06/01/2007 - "This study was designed to evaluate the protective effects of SGL-S23 in an effector phase of arthritis. "
06/01/2007 - "SGL-S23 strongly suppressed K/BxN serum transfer arthritis by inhibiting inflammatory cell infiltration and subsequent destruction of cartilage and bone. "
06/01/2007 - "Stimulation of invariant natural killer T (iNKT) cells with SGL-S23, a novel synthetic glycolipid analog of alpha-galactosylceramide with an elongated sphingosine chain, has been shown to strongly suppress K/BxN serum transfer arthritis. "

Related Drugs and Biologics

1.	Sphingosine
2.	Glycolipids
3.	alpha-galactosylceramide